Characteristics of the participants who reported using a DMT in at least one of the 2015, 2016 and 2017 Australian Multiple Sclerosis Longitudinal Study medication and disease course surveys
| 2015 | 2016 | 2017 | Total observations | |
| Total observations, n | 1089 | 826 | 902 | 2817 |
| Treatment | ||||
| Category 1 DMTs, n (%) | ||||
| Interferon β-1b | 98 (9.0) | 60 (7.3) | 54 (6.0) | 212 (7.5) |
| Interferon β-1a SC | 47 (4.3) | 39 (4.7) | 38 (4.2) | 124 (4.4) |
| Interferon β-1a IM | 70 (6.4) | 43 (5.2) | 37 (4.1) | 150 (5.3) |
| Pegylated interferon β-1a | 44 (4.0) | 41 (5.0) | 55 (6.1) | 140 (5.0) |
| Glatiramer acetate | 147 (13.5) | 114 (13.8) | 109 (12.1) | 370 (13.1) |
| Category 2 DMTs, n (%) | ||||
| Teriflunomide | 63 (5.8) | 58 (7.0) | 79 (8.8) | 200 (7.1) |
| Dimethyl fumarate | 142 (13.0) | 96 (11.6) | 96 (10.6) | 334 (11.9) |
| Category 3 DMTs, n (%) | ||||
| Natalizumab | 124 (11.4) | 102 (12.3) | 118 (13.1) | 344 (12.2) |
| Fingolimod | 330 (30.3) | 237 (28.7) | 283 (31.4) | 850 (30.2) |
| Alemtuzumab | 23 (2.1) | 36 (4.4) | 33 (3.7) | 92 (3.3) |
| Mitoxantrone | 1 (0.1) | 0 (0.0) | 0 (0.0) | 1 (0.0) |
| Age (years), mean (SD) | 51.92 (10.5) | 52.40 (10.6) | 53.46 (9.9) | 52.55 (10.4) |
| MS duration since diagnosis (years), mean (SD) | 12.26 (7.2) | 12.18 (7.4) | 12.24 (7.1) | 12.23 (7.2) |
| Sex, n (%) | ||||
| Female | 883 (81.1) | 666 (80.6) | 732 (81.2) | 2281 (81.0) |
| Male | 206 (18.9) | 160 (19.4%) | 170 (18.8) | 536 (19.0) |
| Highest education, n (%) | ||||
| Primary or secondary school | 278 (25.5) | 195 (23.6) | 233 (25.8) | 706 (25.1) |
| Occupational certificate or diploma | 374 (34.3) | 284 (34.4) | 295 (32.7) | 953 (33.8) |
| University bachelor’s degree | 254 (23.3) | 200 (24.2) | 215 (23.8) | 669 (23.7) |
| University postgraduate degree | 183 (16.8) | 147 (17.8) | 159 (17.6) | 489 (17.4) |
| MS type at survey time, n (%) | ||||
| Relapsing–remitting MS | 920 (84.5) | 702 (85.0) | 740 (82.0) | 2362 (83.8) |
| Secondary progressive MS | 105 (9.6) | 79 (9.6) | 101 (11.2) | 285 (10.1) |
| Primary progressive MS | 64 (5.9) | 45 (5.4%) | 61 (6.8) | 170 (6.0) |
DMT, disease-modifying therapy; IM, Intramuscular; MS, multiple sclerosis; SC, Subcutaneous.